CDSCO Panel Approves Novartis Protocol Amendment Proposal for Ruxolitinib study Dr. Divya Colin4 Jan 2025 5:45 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol...
Intas Pharmaceutical Gets CDSCO Panels Nod to Conduct Phase III clinical trial of Ruxolitinib cream Dr. Divya Colin3 Nov 2024 5:00 PM ISTNew Delhi: Intas Pharmaceutical has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
CDSCO Panel Approves Novartis Protocol Amendment Proposal To Study Ruxolitinib and Panobinostat Dr. Divya Colin30 Jun 2024 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol...
New study unravels role of interferon gamma in autoimmune polyendocrine syndrome type 1: NEJM Medha Baranwal4 Jun 2024 9:45 AM ISTUSA: Recent research has shed light on the pivotal role of interferon gamma in the pathogenesis of autoimmune polyendocrine syndrome type 1 (APS-1),...
Novartis to acquire MorphoSys AG for EUR 68 per share or aggregate of EUR 2.7bn in cash Ruchika Sharma6 Feb 2024 12:30 PM ISTBasel: Novartis has announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a...
GSK Omjjara gets European Commission marketing authorisation Ruchika Sharma29 Jan 2024 4:45 PM ISTLondon: GSK plc has announced the European Commission has granted marketing authorisation for Omjjara (momelotinib), a once-a-day, oral JAK1/JAK2...
Sun Pharma arm signs licensing agreement with Aclaris Therapeutics Ruchika Sharma6 Dec 2023 12:30 PM ISTThe agreement includes an upfront payment of USD 15 million, regulatory and commercial milestones, and royalties.
GSK gets positive EMA Committee opinion recommending Momelotinib for myelofibrosis patients with anaemia Ruchika Sharma15 Nov 2023 2:30 PM ISTLondon: GSK plc has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive...
Treatment with JAK inhibitor for myelofibrosis leads to Mycobacterium marinum skin infection: A case report Medha Baranwal14 July 2023 9:15 AM ISTChina: A recent article published in Clinical, Cosmetic and Investigational Dermatology reports the case of mycobacterium marinum skin infection in...
JAK inhibitor ruxolitinib promising in reducing severity of rare form of sclerosis: NEJM Aditi7 Jun 2023 9:30 AM ISTA study published in The New England Journal of Medicine has mentioned the results of a clinical series demonstrating the role of Janus kinase (JAK)...
Ruxolitinib found efficacious in patient with severe lupus miliaris disseminatus faciei: JAMA case report Dr Manoj Kumar Nayak8 May 2023 8:00 PM ISTResearchers have reported a case in JAMA in which Ruxolitinib was found efficacious in a patient with severe lupus miliaris disseminatus...
Novartis Ruxolitinib Gets CDSCO Panel Okay for Acute and Chronic Graft Versus Host Disease Dr. Divya Colin22 July 2022 6:00 PM ISTNew Delhi: In response to the pharma major Novartis proposal for additional indication of Ruxolitinib Tablets 5/10/15/20 mg, the Subject Expert...
